Technology | Contrast Media | February 02, 2017

Lantheus Medical Imaging Announces FDA Approval of Definity Label Update

Label revision removes cardiac shunt contraindication

Lantheus Medical Imaging, Definity, FDA approval, label update, echocardiography, cardiac shunt contraindication

February 2, 2017 — Lantheus Medical Imaging Inc. announced U.S. Food and Drug Administration (FDA) approval of a label update for Definity Vial for (Perflutren Lipid Microsphere) Injectable Suspension. The update removes the contraindication statement related to use in patients with a known or suspected cardiac shunt from the U.S. Prescribing Information.

Definity is indicated for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border.

A cardiac shunt is a pattern of blood flow in the heart that deviates from the normal path of the circulatory system, which may present in 10 to 35 percent of patients. These patients were previously excluded from receiving a valuable echo contrast study of the left ventricle. The FDA’s decision to remove the contraindication concerning known or suspected cardiac shunts was based on Lantheus’ submission referencing several publications and data supporting the safety of echocardiography contrast products in patients with cardiac shunts. Information concerning administration in patients with a cardiac shunt appears in the Warnings section of the Definity Prescribing Information.

Neil Weissman, M.D., president of MedStar Health Research Institute (Washington, D.C.), professor of medicine at Georgetown University and past president of the American Society of Echocardiography commented, “The echocardiography medical and scientific community has long demonstrated the safety of echocardiographic contrast agents through published clinical studies which has supported the removal of the contraindication for Definity in patients with cardiac shunts. This is particularly noteworthy as Definity is the most widely used echocardiography agent in the U.S. with published data supporting its safety profile across multiple care settings and across gender and race in adults, including those age 65 and older.”

Weissman continued, “This is an important step toward broader acceptance and appropriate use of echo contrast agents, which can safely and cost effectively provide critical information to help clinicians accurately diagnose and manage patients to achieve better outcomes.”

Up to 20 percent of all resting echocardiography studies and up to 30 percent of those conducted in critical care patients can result in suboptimal echocardiograms. A suboptimal image is one in which two or more contiguous left ventricular segments in any of the three apical views cannot be visualized. The use of contrast in suboptimal echocardiograms may help with clinical evaluation of the patient.

For more information: www.lantheus.com

Related Content

Ebit and DiA Imaging Analysis Partner on AI-based Cardiac Ultrasound Analysis
News | Cardiovascular Ultrasound | April 16, 2019
DiA Imaging Analysis has partnered with the Italian healthcare IT company Ebit (Esaote Group), to offer DiA’s LVivo...
DiA Imaging Analysis Introduces LVivo SAX Ultrasound Analysis Tool
Technology | Cardiovascular Ultrasound | April 09, 2019
DiA Imaging Analysis announced the launch of LVivo SAX, a cardiac analysis tool that helps clinicians quickly and...
 The ScImage cloud-based PICOM365 enterprise cardiology is one of the newer generation echo reporting solutions that offers several ways to streamline workflow.

 The ScImage cloud-based PICOM365 enterprise cardiology is one of the newer generation echo reporting solutions that offers several ways to streamline workflow.

Feature | Cardiovascular Ultrasound | April 08, 2019 | Dave Fornell, Editor
Echocardiography reporting systems are usually integrated with, or offered as an add-on module for a ...
Echocardiograms May Help With Patient Selection for Transcatheter Mitral Valve Repair
News | Cardiovascular Ultrasound | March 21, 2019
Clinicians should use echocardiography when determining whether patients with heart failure and a leaking heart valve...
Epsilon Launches EchoInsight Pro Starter Configuration
News | Cardiovascular Ultrasound | February 15, 2019
Epsilon Imaging recently launched the new EchoInsight Pro Starter configuration for those programs that may be budget...
A view of GE Healthcare's volume max, or Vmax, which allows for nearly triple the frame rate speeds on 3-D TEE in a single beat over previous generation systems.

A view of GE Healthcare's volume max, or Vmax, which allows for nearly triple the frame rate speeds on 3-D TEE in a single beat over previous-generation systems.  

Feature | Cardiovascular Ultrasound | January 31, 2019 | Dave Fornell, Editor
The higher expense and lower frame rates of 3-D...
ASE Releases New Guide to Performing Comprehensive Transthoracic Echo Exams
News | Cardiovascular Ultrasound | January 21, 2019
January 21, 2019 – Medical experts have released “...
Videos | Cardiovascular Ultrasound | December 12, 2018
This is an example of the new Fetal HQ heart and vascular software from GE Healthcare for fetal ultrasound.
Hitachi Medical Systems Europe Introduces Third-Generation Intelligent Vector Flow Mapping
News | Cardiovascular Ultrasound | December 07, 2018
Hitachi Medical Systems Europe introduced what it calls the next level of intelligent Vector Flow Mapping (iVFM) at...
Overlay Init